Heliobas Disciple
TB Fanatic
I posted this on the main Coronavirus Thread but copying here.
~~~~~~~~~~
On Saturday, I posted this video of Bill Gates being interviewed on Nov. 4 2021:
www.timebomb2000.com
Bill Gates calls for $1 billion WHO pandemic task force to carry out “germ games”
3min 8sec
View: https://www.youtube.com/watch?v=Tlx8WTKAgVY
One of the things discussed in that video was Gates warning about a smallpox terrorist attack at an airport:
Bill Gates: It'll take probably about a billion a year for a pandemic task force at the WHO level, which is doing the surveillance and actually doing what I call "germ games" where you practice. You say, OK, what if a bioterrorist brought smallpox to 10 airports? You know, how would the world respond to that? There's naturally caused epidemics and bioterrorism caused epidemics that could even be way worse than what we experienced today. And yet the advances in medical sciences should give us tools that, you know, we could do dramatically better.
NOW LOOK WHAT ALSO HAPPENED ON NOV 4th.
(fair use applies)
Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - Form 8-K
11/04/2021 | 03:50pm EST
- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter
- Approximately $13 Million of International Sales for the First Nine Months of 2021 -
- Corporate Update Conference Call Today at 4:30 PM ET
NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2021.
"SIGA's financial results for the first nine months of 2021 include approximately $13 million of international sales, which represents a more than fourfold increase in comparison to the comparable period in 2020. Additionally, we continue to work with Meridian in a new foreign jurisdiction toward finalizing an order that would be similar in size to the initial orders received from Canada in 2020 and early 2021. The timing of the completion of the order has been and may continue to be impacted by the COVID-19 pandemic," said Phil Gomez, CEO of SIGA.
"Looking forward to the fourth quarter of 2021, we are coordinating with our supply chain to deliver up to approximately $113 million in total of oral TPOXX® to the U.S. government, almost 30% of which was delivered in October. This progress highlights the strong and growing revenue base of TPOXX, as well as its continuing importance in orthopox health security preparedness."
[SNIP]
ABOUT SIGA TECHNOLOGIES, INC. and TPOXX
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the U.S. government maintains a stockpile of TPOXX for treatment of smallpox. Over the past decade, the U.S. government has procured, or has current orders for, approximately $705 million of TPOXX for national preparedness. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018. The full label is here: DailyMed - TPOXX- tecovirimat monohydrate capsule. In September 2018, SIGA signed a contract potentially worth more than $600 million with BARDA for procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.
About Smallpox
Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.
SEE ALSO:
www.precisionvaccinations.com
(fair use applies)
Gates Germ-Game Warning Motivates Smallpox Vaccine Discussions
JYNNEOS is an FDA-approved non-replicating smallpox and monkeypox vaccine
Fact checked by Robert Carlson, MD
Published November 8, 2021
Fact checked November 9, 2021
Policy Exchange recently hosted Mr. Bill Gates, Co-Chair of the Bill and Melinda Gates Foundation, and Rt Hon Jeremy Hunt MP, Chair of the Health Select Committee, who discussed the potential of future pandemics.
In a wide-ranging discussion on November 4, 2021, Gates called for a new international Pandemic Task Force, with a budget of about $1 billion per year.
According to Microsoft's founder, governments must invest billions in research and development to prepare for future pandemics and smallpox terror strikes.
This new effort would "germ game" potential pandemics and bioterrorist attacks such as smallpox attacks on airports. The Science Times reported germ games are ‘when government agencies practice scenarios of another pandemic catastrophe.’
“You say, OK, what if a bioterrorist brought smallpox to 10 airports? You know, how would the world respond to that?
“There are naturally-caused epidemics and bioterrorism-caused epidemics that could even be way worse than what we experienced today.”
“And citizens expect their governments not to let that happen again,” Gates commented.
Gates has previously issued similar warnings.
In an April 2015 TED presentation, "The next outbreak? We're not ready," Gates warned of the hazards of a highly contagious virus and a major pandemic, stressing the importance of being prepared.
Based on recent Centers for Disease Control and Prevention (CDC) vaccine advisory committee meetings, the U.S. is focused on the threat of smallpox.
On November 3, 2021, following an introduction by Pablo Sanchez, M.D. Chair of the Orthopoxvirus workgroup, the CDC’s Advisory Committee on Immunization Practices reviewed the two presentations focused on the smallpox vaccine JYNNEOS.
Produced by Bavarian Nordic, JYNNEOS was initially approved in 2019 by the U.S. Food and Drug Administration (FDA) and is indicated for preventing smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
JYNNEOS is the only FDA-approved non-replicating smallpox vaccine and the only FDA-approved monkeypox vaccine for non-military use.
Brett Petersen, M.D., MPH, presented the new proposed ‘clinical guidance for the use of JYNNEOS as it compares to an older smallpox vaccine, ACAM2000, which the ACIP currently recommends.
Many persons with contraindications to vaccination with ACAM2000 (e.g., atopic dermatitis, immunocompromising conditions, breastfeeding, or pregnancy) may receive vaccination with JYNNEOS.
A person can be considered fully immunized two weeks following administration of the second dose of JYNNEOS when clinical studies have demonstrated maximal antibody titers.
As a replication-deficient vaccine, JYNNEOS does not produce a vaccine site lesion that can be used as a marker of successful vaccination.
And routine titer testing is not recommended following vaccination with JYNNEOS to confirm successful administration of the vaccine, given that high seroconversion rates were demonstrated in clinical trials.
However, titer testing could be considered on a case-by-case basis after consultation with public health authorities for select persons with immunocompromising conditions or those working with more virulent orthopoxviruses (variola and monkeypox) to confirm an immune response has been achieved.
Currently, the smallpox vaccine is not recommended for the general public in the USA since smallpox has been eradicated. Routine smallpox vaccination among Americans stopped in 1972.
However, U.S. health officials are prepared to use a vaccine if there were a smallpox outbreak, says the CDC.
Note: Bill Gates publishes various posts at GatesNote.com.
PrecisionVaccinations publishes fact-checked research-based vaccine news.
~~~~~~~~~~
On Saturday, I posted this video of Bill Gates being interviewed on Nov. 4 2021:
CORONA - Main Coronavirus thread
https://citizenfreepress.com/breaking/alyssa-milano-bitten-in-the-ass-by-her-own-vaccine-poll/ Alyssa Milano bitten in the ass by her own Vaccine poll… Posted by Kane on November 5, 2021 11:24 pm
Bill Gates calls for $1 billion WHO pandemic task force to carry out “germ games”
3min 8sec
One of the things discussed in that video was Gates warning about a smallpox terrorist attack at an airport:
Bill Gates: It'll take probably about a billion a year for a pandemic task force at the WHO level, which is doing the surveillance and actually doing what I call "germ games" where you practice. You say, OK, what if a bioterrorist brought smallpox to 10 airports? You know, how would the world respond to that? There's naturally caused epidemics and bioterrorism caused epidemics that could even be way worse than what we experienced today. And yet the advances in medical sciences should give us tools that, you know, we could do dramatically better.
NOW LOOK WHAT ALSO HAPPENED ON NOV 4th.
Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - Form 8-K
- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - -...
www.marketscreener.com
Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - Form 8-K
11/04/2021 | 03:50pm EST
- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter
- Approximately $13 Million of International Sales for the First Nine Months of 2021 -
- Corporate Update Conference Call Today at 4:30 PM ET
NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2021.
"SIGA's financial results for the first nine months of 2021 include approximately $13 million of international sales, which represents a more than fourfold increase in comparison to the comparable period in 2020. Additionally, we continue to work with Meridian in a new foreign jurisdiction toward finalizing an order that would be similar in size to the initial orders received from Canada in 2020 and early 2021. The timing of the completion of the order has been and may continue to be impacted by the COVID-19 pandemic," said Phil Gomez, CEO of SIGA.
"Looking forward to the fourth quarter of 2021, we are coordinating with our supply chain to deliver up to approximately $113 million in total of oral TPOXX® to the U.S. government, almost 30% of which was delivered in October. This progress highlights the strong and growing revenue base of TPOXX, as well as its continuing importance in orthopox health security preparedness."
[SNIP]
ABOUT SIGA TECHNOLOGIES, INC. and TPOXX
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the U.S. government maintains a stockpile of TPOXX for treatment of smallpox. Over the past decade, the U.S. government has procured, or has current orders for, approximately $705 million of TPOXX for national preparedness. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018. The full label is here: DailyMed - TPOXX- tecovirimat monohydrate capsule. In September 2018, SIGA signed a contract potentially worth more than $600 million with BARDA for procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.
About Smallpox
Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.
SEE ALSO:
Gates Germ-Game Warning Motivates Smallpox Vaccine Discussions
JYNNEOS is an FDA-approved non-replicating smallpox and monkeypox vaccine
Gates Germ-Game Warning Motivates Smallpox Vaccine Discussions
JYNNEOS is an FDA-approved non-replicating smallpox and monkeypox vaccine
Fact checked by Robert Carlson, MD
Published November 8, 2021
Fact checked November 9, 2021
Policy Exchange recently hosted Mr. Bill Gates, Co-Chair of the Bill and Melinda Gates Foundation, and Rt Hon Jeremy Hunt MP, Chair of the Health Select Committee, who discussed the potential of future pandemics.
In a wide-ranging discussion on November 4, 2021, Gates called for a new international Pandemic Task Force, with a budget of about $1 billion per year.
According to Microsoft's founder, governments must invest billions in research and development to prepare for future pandemics and smallpox terror strikes.
This new effort would "germ game" potential pandemics and bioterrorist attacks such as smallpox attacks on airports. The Science Times reported germ games are ‘when government agencies practice scenarios of another pandemic catastrophe.’
“You say, OK, what if a bioterrorist brought smallpox to 10 airports? You know, how would the world respond to that?
“There are naturally-caused epidemics and bioterrorism-caused epidemics that could even be way worse than what we experienced today.”
“And citizens expect their governments not to let that happen again,” Gates commented.
Gates has previously issued similar warnings.
In an April 2015 TED presentation, "The next outbreak? We're not ready," Gates warned of the hazards of a highly contagious virus and a major pandemic, stressing the importance of being prepared.
Based on recent Centers for Disease Control and Prevention (CDC) vaccine advisory committee meetings, the U.S. is focused on the threat of smallpox.
On November 3, 2021, following an introduction by Pablo Sanchez, M.D. Chair of the Orthopoxvirus workgroup, the CDC’s Advisory Committee on Immunization Practices reviewed the two presentations focused on the smallpox vaccine JYNNEOS.
Produced by Bavarian Nordic, JYNNEOS was initially approved in 2019 by the U.S. Food and Drug Administration (FDA) and is indicated for preventing smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
JYNNEOS is the only FDA-approved non-replicating smallpox vaccine and the only FDA-approved monkeypox vaccine for non-military use.
Brett Petersen, M.D., MPH, presented the new proposed ‘clinical guidance for the use of JYNNEOS as it compares to an older smallpox vaccine, ACAM2000, which the ACIP currently recommends.
Many persons with contraindications to vaccination with ACAM2000 (e.g., atopic dermatitis, immunocompromising conditions, breastfeeding, or pregnancy) may receive vaccination with JYNNEOS.
A person can be considered fully immunized two weeks following administration of the second dose of JYNNEOS when clinical studies have demonstrated maximal antibody titers.
As a replication-deficient vaccine, JYNNEOS does not produce a vaccine site lesion that can be used as a marker of successful vaccination.
And routine titer testing is not recommended following vaccination with JYNNEOS to confirm successful administration of the vaccine, given that high seroconversion rates were demonstrated in clinical trials.
However, titer testing could be considered on a case-by-case basis after consultation with public health authorities for select persons with immunocompromising conditions or those working with more virulent orthopoxviruses (variola and monkeypox) to confirm an immune response has been achieved.
Currently, the smallpox vaccine is not recommended for the general public in the USA since smallpox has been eradicated. Routine smallpox vaccination among Americans stopped in 1972.
However, U.S. health officials are prepared to use a vaccine if there were a smallpox outbreak, says the CDC.
Note: Bill Gates publishes various posts at GatesNote.com.
PrecisionVaccinations publishes fact-checked research-based vaccine news.
Last edited:
worshipers are talking about it, then you can bet they're going to release it. That's what they do. They want you to know it's coming.
